REVB Revelation Biosciences, Inc.
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
What changed
Recent filings, trades and moves- Nov 5 8-K: Earnings results
- Nov 5 Quarterly report (10-Q) filed

- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 9
- List Date
- 2022-01-11
- CIK
- 0001810560
- Last Earnings
- Aug 6
- Headquarters
- San Diego, CA
- Homepage
- https://www.revbiosciences.com
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operat…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|
| Jan | -70.51% | 53.45% | -42.48% | -64.14% | -37.59% | -32.25% |
| Feb | -50.76% | -78.45% | 14.78% | -12.53% | -29.79% | -31.35% |
| Mar | -14.29% | -40.91% | -24.73% | -24.64% | -6.98% | -22.31% |
| Apr | -17.39% | -18.18% | -20.78% | 17.31% | -8.13% | -9.43% |
| May | -39.20% | 1.94% | -10.23% | -71.83% | -2.23% | -24.31% |
| Jun | 152.22% | -8.73% | -0.52% | -8.87% | -5.50% | 25.72% |
| Jul | -45.87% | -12.76% | -11.76% | 1.22% | -8.65% | -15.56% |
| Aug | -22.25% | -19.96% | -22.30% | 13.11% | -1.96% | -10.67% |
| Sep | -32.75% | 2.13% | -19.64% | -47.41% | -17.19% | -22.97% |
| Oct | 20.39% | -15.32% | 1.75% | -14.38% | -28.13% | -7.14% |
| Nov | -25.23% | 17.96% | -7.65% | -20.45% | -2.72%* | -7.62% |
| Dec | -17.71% | -34.12% | -51.47% | -16.34% | -- | -29.91% |
| Total | -96.69% | -93.02% | -91.17% | -97.56% | -82.06% | -92.10% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report: REVB
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 7/10)
Key Drivers:
- Negative technical indicators, including bearish MACD and RSI
- High stock volatility with a negative beta relative to the market
- Lack of recent news headlines to provide catalysts for the stock
Primary Risks:
- Continued decline in stock price driven by bearish momentum
- Increased risk due to high volatility and negative correlation with the market
Investment Thesis: REVB is likely to experience further decline in the short-term due to bearish technical indicators and lack of positive news catalysts. However, a potential rebound could occur if the company reports strong earnings or announces positive developments.
Recent News Sentiment Impact: None (no recent news headlines available)
Technical Analysis
Trend Direction:
- Short-term: Bearish
- Medium-term: Bearish
- Long-term: Neutral
Support/Resistance Levels:
- Upper Bollinger Band: $1.14
- Middle Bollinger Band: $0.95
- Lower Bollinger Band: $0.76
Momentum Signals:
- RSI (14): 30.79 (neutral)
- MACD: -0.06 / Signal: -0.01 / Histogram: -0.05 (bearish)
Volume Analysis:
- Volume SMA 20: 113052.70
- On-Balance Volume (OBV): 20782914.90
- Volume Rate of Change: 212.69%
News & Sentiment Analysis
Recent Headlines Summary: None (no recent news headlines available)
Sentiment Assessment: Neutral
Catalyst Identification: None
Market Narrative: Lack of recent news headlines to provide market narrative.
Risk & Volatility Assessment
Risk Level: High
Beta Interpretation: Stock moves opposite to the market due to negative beta (-0.46).
Volatility Regime: Very high volatility (2.77)
Options Market Signals:
- IV rank: Not applicable
- Put/call ratios: Not applicable
- Unusual activity: None
Downside Protection: Lower Bollinger Band ($0.76) provides support.
Market Context & Positioning
Sector Performance: Weak performance relative to the sector.
Institutional Activity: High institutional interest indicated by volume patterns.
Correlation Analysis: Stock moves opposite to the market (R-squared interpretation).
Relative Valuation: Neutral within trading range.
Key Levels & Action Items
Critical Price Levels:
- Upper Bollinger Band ($1.14) - potential resistance
- Lower Bollinger Band ($0.76) - potential support
Breakout/Breakdown Levels:
- SMA 20: $0.95 (potential breakout/breakdown)
- SMA 50: $1.01 (potential breakout/breakdown)
Time-Sensitive Catalysts:
- Earnings date: 2025-08-08
- Potential product launch or regulatory update
Risk Management:
- Stop-loss levels: below Lower Bollinger Band ($0.76) and SMA 20 ($0.95)
- Position sizing considerations: Conservative approach due to high volatility.
Note: The analysis is based on the provided data, but it's essential to consider other relevant factors that might not be included in this report.
REVB Options Activity & IV Rank
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Loading the implied volatility surface…
Loading the implied volatility smile…
Risk Metrics
Analysis Details
Data Points: 250
Period: 252 trading days
High volatility - stock moves more than market
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $40K | #6058 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
REVB Institutional Ownership (13F)
Filings for 2026-06-30 · 4 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
REVB Insider Trading (Form 4)
Latest: 2026-08-18| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-18 | Jess Roper | Director | Award (A) | +32,011 | — | EDGAR | |
| 2026-08-18 | James Rolke | Chief Executive Officer | Award (A) | +208,076 | — | EDGAR | |
| 2026-08-18 | Lakhmir S Chawla | Director | Award (A) | +32,011 | — | EDGAR | |
| 2026-08-18 | Jennifer Carver | Director | Award (A) | +32,011 | — | EDGAR | |
| 2026-08-18 | Chester Stanley Zygmont III | Chief Financial Officer | Mixed Grant +208,073 · Gift +0 |
+208,073 | — | EDGAR |
REVB Insider Holdings
5 insiders · @ $3.94| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | James Rolke | Chief Executive Officer | 60,402 | $238.0K | $0 | 1 | 2026-08-18 |
| 2 | Chester Stanley Zygmont III | Chief Financial Officer | 42,877 | $168.9K | $0 | 1 | 2026-08-18 |
| 3 | Jess Roper | Director | 6,406 | $25.2K | $0 | 1 | 2026-08-18 |
| 4 | Jennifer Carver | Director | 6,396 | $25.2K | $0 | 1 | 2026-08-18 |
| 5 | Lakhmir S Chawla | Director | 6,310 | $24.9K | $0 | 1 | 2026-08-18 |
REVB Board & Officers
As of SEC filings through Aug 18, 2026Directors 4
- James Rolke · since Jan 10, 2022
- Jennifer Carver · since Jan 10, 2022
- Jess Roper · since Jan 10, 2022
- Lakhmir S Chawla · since Sep 27, 2023
Officers 2
- James Rolke · Chief Executive Officer · since Jan 10, 2022
- Chester Stanley Zygmont III · Chief Financial Officer · since Jan 10, 2022
Changes in the last 10 years (36)
| May 23, 2025 | The company announced the departure of George F Tidmarsh from the board in an SEC filing |
| Sep 27, 2023 | The company announced the departure of Curt H LaBelle from the board in an SEC filing |
| Sep 27, 2023 | Lakhmir S Chawla became a director |
| Apr 18, 2023 | George F Tidmarsh no longer listed as a 10% owner in SEC filings |
| Jan 10, 2022 | The company announced the departure of William Howard Carson from the board in an SEC filing |
| Jan 10, 2022 | The company announced the departure of Sean H Fitzpatrick from the board in an SEC filing |
| Jan 10, 2022 | The company announced the departure of Sean H Fitzpatrick as Chief Financial Officer in an SEC filing |
| Jan 10, 2022 | The company announced the departure of Robert D Nicholson from the board in an SEC filing |
| Jan 10, 2022 | The company announced the departure of David Dobkin from the board in an SEC filing |
| Jan 10, 2022 | The company announced the departure of Barry Dennis from the board in an SEC filing |
| Jan 10, 2022 | The company announced the departure of Anthony Hayes from the board in an SEC filing |
| Jan 10, 2022 | The company announced the departure of Andreas Typaldos from the board in an SEC filing |
| Jan 10, 2022 | Jess Roper became a director |
| Jan 10, 2022 | Jennifer Carver became a director |
| Jan 10, 2022 | James Rolke became a director |
| Jan 10, 2022 | James Rolke became Chief Executive Officer |
| Jan 10, 2022 | George F Tidmarsh became a director |
| Jan 10, 2022 | George F Tidmarsh became a 10% owner |
| Jan 10, 2022 | Curt H LaBelle became a director |
| Jan 10, 2022 | Chester Stanley Zygmont III became Chief Financial Officer |
| Oct 13, 2021 | Lawrence Feis became a 10% owner |
| Oct 13, 2021 | Feis Equities LLC became a 10% owner |
| Mar 11, 2021 | William Howard Carson became a director |
| Oct 8, 2020 | Paul J Glazer became a 10% owner |
| Oct 8, 2020 | Glazer Capital, LLC became a 10% owner |
| Oct 7, 2020 | Sean H Fitzpatrick became a director |
| Oct 7, 2020 | Sean H Fitzpatrick became a 10% owner |
| Oct 7, 2020 | Sean H Fitzpatrick became Chief Financial Officer |
| Oct 7, 2020 | Robert D Nicholson became a director |
| Oct 7, 2020 | Kimon Angelides became a director |
| Oct 7, 2020 | David Dobkin became a director |
| Oct 7, 2020 | Barry Dennis became a director |
| Oct 7, 2020 | Anthony Hayes became a director |
| Oct 7, 2020 | Andreas Typaldos became a director |
| Oct 7, 2020 | Andreas Typaldos became a 10% owner |
| Oct 7, 2020 | Andreas Typaldos became Chief Executive Officer |
- Prev
- 1
Not reported recently (7)
- Lawrence Feis · Last reported as a 10% owner in an SEC filing dated Jan 11, 2022
- Feis Equities LLC · Last reported as a 10% owner in an SEC filing dated Jan 11, 2022
- Glazer Capital, LLC · Last reported as a 10% owner in an SEC filing dated Sep 23, 2021
- Paul J Glazer · Last reported as a 10% owner in an SEC filing dated Sep 23, 2021
- Sean H Fitzpatrick · Last reported as a 10% owner in an SEC filing dated Dec 31, 2020
- Andreas Typaldos · Last reported as Chief Executive Officer in an SEC filing dated Dec 31, 2020
- Kimon Angelides · Last reported as a director in an SEC filing dated Oct 9, 2020
REVB Proposed Insider Sales (Form 144)
Latest: 2023-09-28What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2023-09-28 | GEORGE F TIDMARSH & COURTNEY MOULDS CO-TTEE THE TIDMARSH LIVING TRUST U/A DTD 09/26/2016 | Director | 1,429 | $986 | 2023-09-28 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-05 | Earnings results | EDGAR |
| 2026-08-19 | Director or officer change | EDGAR |
| 2026-08-06 | Earnings results | EDGAR |
| 2026-07-13 | Material agreement · Shareholder rights change · Bylaws or fiscal year change · Regulation FD disclosure | EDGAR |
| 2026-06-24 | Director or officer change · Bylaws or fiscal year change · Shareholder vote results | EDGAR |
| 2026-06-01 | Other events | EDGAR |
| Filing Date | Accession | Link |
|---|
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
REVB vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.26T | 46.1 | +45.5% | +31.4% | 24 |
| JNJ Johnson & Johnson | $679.1B | 42.1 | +7.8% | +33.8% | 66 |
| ABBV ABBVIE INC. | $518.4B | 50.1 | +10.7% | +26.9% | 35 |
| MRK Merck & Co., Inc. | $366.7B | 150.7 | +4.9% | +37.3% | 40 |
| NVS Novartis AG | $309.1B | — | — | +15.3% | 42 |
| AZN AstraZeneca PLC | $293.7B | — | — | +100.8% | 0 |
| ABT Abbott Laboratories | $191.4B | 40.5 | +10.0% | −11.9% | 18 |
| NVO Novo-Nordisk A/S | $182.4B | — | — | −23.3% | 13 |
| REVB Revelation Biosciences, Inc. Common Stoc | $2M | — | — | −82.7% | — |
| Peer median | $337.9B | 46.1 | +10.0% | +29.1% | 30 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.